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OBJECTIVE—We characterized ﬂuctuations between states of
glycemia in progressors to type 1 diabetes and studied whether
those ﬂuctuations are related to the early C-peptide response to
oral glucose.
RESEARCH DESIGN AND METHODS—Oral glucose toler-
ance tests (OGTTs) from differing states of glycemia were
compared within individuals for glucose and C-peptide. Dysgly-
cemic OGTTs (DYSOGTTs) were compared with normal OGTTs
(NLOGTT), while transient diabetic OGTTs (TDOGTTs) were
compared with subsequent nondiabetic OGTTs and with OGTTs
performed at diagnosis.
RESULTS—Of 135 progressors with four or more OGTTs, 30
(22%) went from NLOGTTs to DYSOGTTs at least twice. Area
under the curve (AUC) glucose values from the second
NLOGTT were higher (P  0.001) than values from the ﬁrst
NLOGTT. Among 98 progressors whose DYSOGTTs and NLOGTTs
were synchronized for the time before diagnosis, despite higher
glucose levels (P  0.01 at all time points) in the DYSOGTTs, 30-
to 0-min C-peptide difference values changed little. Likewise, 30-
to 0-min C-peptide difference values did not differ between
TDOGTTs and subsequent (within 3 months) nondiabetic OGTTs
in 55 progressors. In contrast, as glucose levels increased overall
from the ﬁrst to last OGTTs before diagnosis (P  0.001 at every
time point, n  207), 30- to 0-min C-peptide difference values
decreased (P  0.001).
CONCLUSIONS—Glucose levels ﬂuctuate widely as they grad-
ually increase overall with progression to type 1 diabetes. As
glucose levels increase, the early C-peptide response declines. In
contrast, glucose ﬂuctuations are not related to the early C-
peptide response. This suggests that changes in insulin sensitivity
underlie the glucose ﬂuctuations. Diabetes 59:2386–2389,
2010
G
lucose levels can ﬂuctuate substantially during
the progression to type 1 diabetes (1). In this
report, we examine glucose variability and ex-
plore its basis by comparing the C-peptide
response to oral glucose between states of glycemia. The
ﬁndings provide additional insights into the metabolic
progression to type 1 diabetes.
RESEARCH DESIGN AND METHODS
Diabetes Prevention Trial–Type 1 (DPT-1) participants and procedures have
been described in detail (2,3). All participants were islet cell autoantibody
(ICA)–positive relatives of type 1 diabetes patients. Those analyzed for this
report participated in either the parenteral insulin (2) or oral insulin (3) trials.
The interventions for the parenteral and oral trials were recombinant
human ultralente insulin and recombinant human insulin crystals, respec-
tively. Visit intervals were 6 months. Diagnoses of type 1 diabetes were
frequently determined from the oral glucose tolerance tests (OGTTs) at
routine visits. OGTTs in the diabetic range were conﬁrmed with another OGTT
(unless symptoms occurred or there was marked fasting hyperglycemia).
Laboratory measures. Plasma glucose was measured by the glucose oxidase
method. Insulin and C-peptide were measured by radioimmunoassay. The
interassay coefﬁcient of variation for the C-peptide assay was 6.9% in a
reference pool with relatively high values and 7.8% in a reference pool with
relatively low values. Fasting C-peptide values 0.2 ng/ml were assigned a
value of 0.1 ng/ml for the analyses. OGTTs included in the analysis had
complete glucose and C-peptide measurements at all time points.
Data analysis. A dysglycemic OGTT (DYSOGTT) was deﬁned as any of the
following: impaired fasting glucose (fasting glucose value 100–125 mg/dl);
indeterminate (30-, 60-, and/or 90-mm glucose values 200 mg/dl); and
impaired glucose tolerance (2-h glucose value 140–199 mg/dl). The thresholds
for a diabetic range OGTT were a fasting glucose value 126 mg/dl and/or a
2-h glucose value 200 mg/dl. The OGTTs that were not dysglycemic and not
in the diabetic range were considered to be normal (NLOGTT). The 30- to
0-min C-peptide difference, deﬁned as the fasting C-peptide value subtracted
from the 30-min C-peptide value, was used to indicate the early C-peptide
response.
Since the early C-peptide response diminishes with progression to type 1
diabetes (4), it was necessary to take into account the inﬂuence of the time
from diagnosis that the DYSOGTTs and NLOGTTs were performed. Thus,
OGTTs were paired according to the ﬁrst NLOGTT to the subsequent last
DYSOGTT, the ﬁrst DYSOGTT to the subsequent last NLOGTT, and a NLOGTT
and a DYSOGTT that were synchronized to nearly the same time (on average)
before diagnosis. The synchronization was performed by pairing the ﬁrst
DYSOGTT with the last NLOGTT (both after randomization), as long as those
OGTTs were within 2 years of each other. A transient diabetic OGTT
(TDOGTT) was deﬁned as an OGTT in the diabetic range that was followed by
an OGTT that was not in the diabetic range (NDOGTT). If a participant had
more than one transient OGTT, the ﬁrst was used for the analysis.
Paired and unpaired t tests and the Wilcoxon rank-sum test were used to
assess differences. Nonparametric testing was utilized, particularly in analyses
that involved OGTTs in the diabetic range because of their glucose distribu-
tions. The trapezoidal rule was used to calculate OGTT areas under the curve
(AUCs). SAS version 9.1.3 was used for the analyses. All P values are two
sided.
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There were 258 progressors to type 1 diabetes in the DPT-1
trials, of whom 207 ([mean  SD] 11.4  7.8 years, 58%
male) were studied. All had a baseline OGTT and at least
one OGTT during follow-up.
Of 135 progressors from both the parenteral and oral
insulin trials with a minimum of four OGTTs, 30 (22%) had
an alternating OGTT pattern (not necessarily consecutive)
of normal, dysglycemic, normal again, and then dysglyce-
mic again over their course of progression to type 1
diabetes. AUC glucose values from those OGTTs are
shown in Fig. 1. As expected, there were signiﬁcant
increases in AUC glucose values when the DYSOGTTs
were compared with their prior NLOGTTs (P  0.001 for
each difference). AUC glucose values from the second
NLOGTTs were signiﬁcantly higher than those from the
ﬁrst NLOGTTs (P  0.001). Also, AUC glucose values from
the second DYSOGTTs were signiﬁcantly higher than
those from the ﬁrst DYSOGTTs (P  0.01).
We assessed whether the state of glycemia was related
to the early insulin response to an oral glucose challenge.
For this purpose, we used the 30- to 0-min C-peptide
difference as a measure of early insulin secretion (4).
Table 1 shows early C-peptide response values according
to pairings of DYSOGTTs and NLOGTTs (see RESEARCH
DESIGN AND METHODS). The early C-peptide response was
substantially lower (P  0.001) in the DYSOGTTs (P 
0.01 for both the parenteral and oral trials separately)
when they occurred after the NLOGTTs (NL3DYSGLY;
n  146). However, when the DYSOGTTs preceded the
NLOGTTs (DYSGLY3NL; n  70), the early C-peptide
response from the DYSOGTTs did not differ signiﬁcantly
from that of the NLOGTTs (nor did they differ when the
trials were analyzed separately). In fact, the early C-
peptide response tended to be higher in the DYSOGTTs.
When the DYSOGTTs and the NLOGTTs were synchro-
nized for the time before diagnosis (SYNCH; n  98), the
early C-peptide response was similar between the
NLOGTTs and the DYSOGTTs (also when the trials were
analyzed separately). Thus, when the time to diagnosis
was minimized as a factor, the early C-peptide response
did not vary between the normal and dysglycemic
states. In addition, no signiﬁcant difference was found
between the normal and dysglycemic states in the ratio
of the C-peptide response over the glucose response
from 0 to 30 min.
We examined the entire glucose and C-peptide curves
from the OGTTs among SYNCH, the group whose
DYSOGTTs and NLOGTTs were synchronized to the same
time before diagnosis (Fig. 2). As expected, glucose levels
(Fig. 2A) from the DYSOGTTs were signiﬁcantly higher
(P  0.01) at every OGTT time point. The differences were
especially apparent from 60 to 120 min. Even though
glucose levels were higher from the DYSOGTTs, C-peptide
levels (Fig. 2B) were also signiﬁcantly higher in the fasting
state (P  0.05), at 90 min (P  0.05), and at 120 min (P 
0.001). The sum of the differences between the 30-min
C-peptide value and the subsequent values during the
OGTT was signiﬁcantly higher in the DYSOGTTs than in
the NLOGTTs (3.20  3.47 ng/ml vs. 2.14  3.55 ng/ml, P 
0.008). BMI values did not differ between DYSOGTTs and
NLOGTTs in 49 paired measurements concurrent with the
paired DYSOGTTs and NLOGTTs (19.9  5.2 kg/m
2 vs.
19.6  4.9 kg/m
2, respectively).
Among 60 progressors with TDOGTTs, we analyzed data
from 55 who had a nondiabetic OGTT (NDOGTT) within 3
months ([mean  SD] 36  16 days) of the TDOGTT.
Glucose levels (online appendix Fig. 1A, available at
http://diabetes.diabetesjournals.org/cgi/content/full/
db10-0534/DC1) were higher in the TDOGTTs at the later
time points (P  0.01 at 60 min; P  0.001 at both 90 and
120 min). Despite those higher glucose levels in the
TDOGTTs, C-peptide levels (online appendix Fig. 1B) were
similar at all time points, except for higher 120-min
C-peptide levels (P  0.01) in the TDOGTTs.
Similar to the ﬁndings from the comparison between the
DYSOGTTs and the NLOGTTs, the early C-peptide re-
sponse did not signiﬁcantly differ between the TDOGTTs
and the NDOGTTs. Also, there was no signiﬁcant differ-
ence in the ratio of the C-peptide response over the
glucose response from 0 to 30 min.
Of the 55 TDOGTTs analyzed above, 38 also had a
subsequent OGTT at the time of diagnosis (DOGTT). The
mean  SD difference in time from the TDOGTTs to
the DOGTTs was 0.9  0.8 years. Glucose levels (online
appendix Fig. 2A) were signiﬁcantly higher at every time
point in the DOGTTs than in the TDOGTTs, especially
postchallenge (P  0.001 for all time points 30 min).
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FIG. 1. Shown is a sequence of alternating NLOGTTs and DYSOGTTs in
progressors to type 1 diabetes. Each point represents the mean AUC
glucose from the OGTTs. The mean time before diagnosis is shown for
each of the OGTTs. There were signiﬁcant increases in the AUC
glucose from each of the NLOGTTs to their subsequent respective
DYSOGTTs. There were also signiﬁcant increases from the ﬁrst
NLOGTTs to the second NLOGTTs and from the ﬁrst DYSOGTTs to the
second DYSOGTTs.
TABLE 1
The early C-peptide (ng/ml) response (30–0 minutes) according to the sequence of NLOGTT and DYSOGTT pairs before diagnosis
NL3DYSGLY (n  146) DYSGLY3NL (n  70) SYNCH (n  98)**
NLOGTT DYSOGTT NLOGTT DYSOGTT NLOGTT DYSOGTT
30–0 minutes* 2.45  1.25 2.01  1.64† 1.96  1.11 2.25  2.00 2.24  1.38 2.27  1.87
Years to diabetes* 2.97  1.32 0.63  0.45 1.31  0.81 2.90  1.22 1.66  0.83 1.72  0.97
*Data are mean  SD. **OGTTs synchronized (SYNCH) to the time before diagnosis. †P  0.001 vs. NLOGTT.
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cantly lower in the DOGTTs at every postchallenge time
point (P  0.01) after 30 min. The early C-peptide response
was also signiﬁcantly lower in the DOGTTs (P  0.001)
than in the TDOGTTs.
Figure 3 shows the C-peptide response relative to the
glucose response from the fasting state to 30 min in the
serial TDOGTTS, NDOGTTs, and DOGTTs from the 38
progressors. The C-peptide response relative to the glu-
cose response was greater in both the TDOGTTs (P 
0.001) and the NDOGTTs (P  0.017) than in the DOGTTs.
There was no signiﬁcant difference between the TDOGTTs
and the NDOGTTs.
In 207 progressors who had two OGTTs, glucose levels
increased overall from the ﬁrst ([mean  SD] 2.8  1.4
years before diagnosis) to the last OGTTs (0.6  0.5 years
before diagnosis) at every time point. In contrast with the
lack of change in the early C-peptide response between
states of glycemia, the early C-peptide response declined
markedly from the ﬁrst OGTT to the last OGTT ([mean 
SD] 2.38  1.25 ng/dl to 1.87  1.11 ng/dl; P  0.001).
DISCUSSION
We have previously shown that on average glucose levels
increase over time with progression to type 1 diabetes (5).
However, the data in this report suggest that within the
individual, glucose levels do not necessarily increase in a
simple, linear manner; rather there can be wide ﬂuctua-
tions that occur on a background of gradually increasing
glucose levels. The overall picture can perhaps best be
described as a kind of ratcheting, as is evident in Fig. 1.
The second normal OGTT did not have the same degree of
“normalcy” as the ﬁrst normal OGTT. The data indicate
that this pattern extends even into the higher ranges of
glycemia as the onset of type 1 diabetes approaches.
There appear to be at least two distinct patterns of
change in glucose levels during the course of progression
to type 1 diabetes, each occurring through a different
mechanism. In one pattern, glucose levels increase over
time as the early C-peptide response decreases. This
pattern was evident when the ﬁrst and last OGTTs were
compared. The data suggest that the increasing glucose is
at least in part attributable to a decline in early insulin
secretion.
The second pattern, characterized by wide ﬂuctuations
of glucose levels, contrasts with the ﬁrst pattern in that the
excursions into the higher glucose range do not appear to
be associated with a decrease in the early C-peptide
response. The early C-peptide response was similar be-
tween the DYSOGTTs and NLOGTTs when they were
synchronized to the time before diagnosis. Also, the early
C-peptide response did not differ between the TDOGTTs
and their subsequent NDOGTTs. Moreover, there were no
signiﬁcant differences in the ratio of the C-peptide re-
sponse over the glucose response from 0 to 30 min
between the DYSOGTTs and the NLOGTTS and between
the TDOGTTs and the NDOGTTs. Thus, two separate
analyses at different ranges of glycemia were consistent in
showing a lack of association between glucose ﬂuctua-
tions and the early C-peptide response.
The data appear to indicate that differences in the early
C-peptide response between DYSOGTTs and NLOGTTs
are a function of the time before diagnosis when the OGTT
is performed. The fact that the early C-peptide response
tended to be higher in the OGTT that came ﬁrst, and was
independent of the state of glycemia, is consistent with the
decline in the early C-peptide response with progression to
type 1 diabetes.
Since glucose excursions were not related to the early
C-peptide response, variation in glucose sensitivity could
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FIG. 2. Shown are glucose (A) and C-peptide (B) values (mean  SD)
for paired NLOGTTs and DYSOGTTs that were synchronized on aver-
age to the time before diagnosis in progressors to type 1 diabetes. As
expected, the glucose values from the DYSOGTTs were substantially
higher at every time point. Even though glucose levels were higher
from the DYSOGTTs, C-peptide values were also signiﬁcantly higher in
the fasting state and at 90 and 120 min.
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FIG. 3. Shown are C-peptide responses in relation to glucose responses
from 0 to 30 min in the TDOGTTs, the subsequent NDOGTTs (within 3
months), and the DOGTTs in progressors to type 1 diabetes. The ratio
of the C-peptide response over the glucose response from 0 to 30 min
was signiﬁcantly higher in both the TDOGTTs and the NDOGTTs than
in the DOGTTs (median values are shown).
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icantly higher when they were associated with the
DYSOGTTs, the higher later OGTT C-peptide values in the
DYSOGTTs is consistent with insulin data in nonobese
adults with impaired glucose tolerance (6) and adults with
diabetes (6,7). Data from other studies lend some support
to the view that insulin resistance could be involved in the
pathogenesis of type 1 diabetes (8–12). Interestingly, it
appears that increased insulin sensitivity could contribute
to the remissions that occur following the diagnosis of
type 1 diabetes (13,14).
The DOGTTs had much higher glucose levels and much
lower C-peptide levels and early C-peptide responses than
did the TDOGTTs. Thus, -cell function is much more
impaired when an OGTT is diagnostic of type 1 diabetes
than when it is transiently in the diabetic range. However,
those with TDOGTTs represent a potential high risk target
population for type 1 diabetes prevention trials.
Excursions into higher glucose ranges could exacerbate
the loss of -cell function through factors such as gluco-
toxicity (15). Therefore, it seems reasonable to consider
interventions that would decrease glucose variability, and
perhaps ultimately, preserve -cell function.
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